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 The PI3K/AKT/mTOR signaling pathway regulates cell proliferation, survival and 
angiogenesis. The mammalian target of rapamycin (mTOR) is a protein kinase ubiquitously 
expressed within cells that regulates cell growth and survival by integrating nutrient and 
hormonal signals. mTOR exists in two complexes, mTORC1 and mTORC2. Hyperactivation 
of the mTOR protein has been linked to development of cancer, raising mTOR as an attractive 
target for cancer therapy.  Prodigiosin (PG) and Obatoclax (OBX), two members of the 
prodiginines family, are small molecules with anticancer properties which are currently under 
clinical trials. In the present paper, we demonstrate that mTOR is a molecular target of both 
prodiginines in melanoma, a highly drug-resistant cancer model. The inhibition of mTORC1 
and mTORC2 complexes by PG or OBX resulted in a loss of AKT phosphorylation at S473, 
preventing its full activation, with no significant effect on T308. The strongest activity 
inhibition (89%) was induced by PG on mTORC2. Binding assays using Surface Plasmon 
Resonance (SPR) provide kinetic and affinity data of the interaction of these small molecules 
with mTOR. In addition, in silico modelling produced a detailed atomic description of the 
binding modes. These results provide new data to understand the mechanism of action of 
these molecules, and provide new structural data that will allow the development of more 
specific mTOR inhibitors for cancer treatment.  
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1. Introduction    
 
 Prodigiosin (PG) and Obatoclax (OBX) are two prodiginine family members which 
have emerged as promising anticancer drugs and are currently in clinical trials. Prodiginines 
are bacterial metabolites with a pyrrolylpyrromethene skeleton which have shown 
immunosuppressive and anticancer properties. PG has shown apoptotic activity against 
several cancer cell types with low cytotoxicity in non-malignant cells. The National Cancer 
Institute (dtp.nci.nih.gov) tested prodigiosin (and some of its derivates) against a collection of 
~ 60 cell lines with an average IC50 (for PG) of 2.1 µM (1). It has been described that the 
apoptotic process triggered by PG is mediated through the mitochondrial pathway and 
involves the induction of the proapoptotic gene NAG-1 (2). Nevertheless, the molecular target 
of this agent is still unknown. Further studies are also necessary to understand the mechanism 
of action of OBX. OBX is a synthetic indolylprodigiosin derivative, which was developed by 
GeminX Pharmaceuticals (recently acquired by Cephalon) and was described as a BH3 
mimetic drug (3).  
 In the present report we identify the mammalian target of rapamycin (mTOR) as a new 
molecular target of the prodiginines. mTOR is an evolutionarily conserved serine/threonine 
protein kinase which is constituted by two signaling complexes: mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2). Both complexes have specific effects on 
distinct cellular functions, such as controlling mRNA translation, ribosome biogenesis, 
autophagy and metabolism (4-6). mTORC2 phosphorylates AGC kinases such as AKT, 
serum- and glucocorticoid-induced protein kinase-1 (SGK1) and protein kinase C-alpha 
(PKCα) (7-9). AKT is one of the best-known downstream effectors of phosphatidylinositol-3 
kinase (PI3K). Complete AKT activation depends on phosphoinositide-dependent kinase-1 
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(PDK1) and mTORC2, which phosphorylate AKT at two key sites: the activation loop (T308) 
and the C-terminal hydrophobic motif (S473), respectively (10, 11). mTOR signaling is 
regulated through a network of feedback loops, protein partners, substrates, and regulators 
(12, 13). Among them, PRAS40 (proline-rich AKT substrate 40 kDa) is a key regulator of 
mTORC1. Moreover, in contrast to mTORC2, which contains rictor (rapamycin-insensitive 
companion of mTOR), mTORC1 contains raptor (regulatory associated protein of mTOR), 
which positively regulates mTOR activity and functions as a scaffold for recruiting mTORC1 
substrates (14, 15). PRAS40 interacts with raptor in insulin-deprived cells and inhibits the 
activation of mTORC1 pathway (16). mTORC1 regulates protein synthesis through S6-kinase 
and the translation repressor protein 4E-BP1. mTORC1 phosphorylates the hydrophobic motif 
of p70S6K on T389 (17). On the other hand, phosphorylation of 4E-BP1 at S65 by mTORC1 
prevents the binding of 4E-BP1 to the eIF4E translation initiation factor activating cap-
dependent translation (13).  
 Interest in identifying and developing new mTOR inhibitors has increased since the 
second generation of mTOR inhibitors showed encouraging results in the treatment of 
different types of cancer, including melanoma (18). Melanoma is an extremely aggressive 
disease with high metastatic potential and notoriously strong resistance to cytotoxic agents. 
Development of resistance has been related to the presence of different feedback loops that 
link both PI3K/AKT/mTOR and mitogen activated protein kinase (MAPK) pathways. These 
pathways are critical to melanoma progression and both are deregulated in melanoma, but not 
in normal cells (19, 20). Thus, compounds that counteract these feedback loops are considered 
in cancer therapy.  
 Here, we report that prodiginines inhibit both mTORC1 and mTORC2 complexes and 
thus counteract the S6K-1/IRS-1 negative feedback loop in melanoma. Moreover, binding 
assays provide data on the stability and affinity of the interaction between these small 
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molecules and mTOR. In addition, we describe several of the recognition motifs involved in 
these interactions by in silico model. 
 




 Prodigiosin (2-methyl-3-pentyl-6-methoxyprodigiosene) was provided by Dr. R. J. 
Schultz of the National Cancer Drug Synthesis and Chemistry Branch Chemotherapeutic 
Agents Repository (Bethesda, MD). Obatoclax, a synthetic indol-containing prodiginine, was 
provided by Dr. Roberto Quesada of the University of Burgos (Supplementary Fig. 1). 
Rapamycin (FRAP1/mTOR inhibitor) was purchased from Invitrogen (Carlsbad, CA). All 
stock solutions were diluted in DMSO and stored at -20ºC. 
 
2.2. Cell lines and Culture Conditions 
 
Human melanoma cancer cell lines SK-MEL-28 and SK-MEL-5 were purchased from 
American Type Culture Collection (Manassas, VA). 
Stable control, mTOR knockdown and raptor knockdown human colon cancer cells 
SW480 were generated using lentivirus-based shRNA targeting mTOR or raptor as described 
in (21).  
All cell types were cultured in Dulbecco´s Modified Eagle´s Medium (DMEM, 
Biological Industries, Beit Haemek, Israel) supplemented with 10% heat-inactivated foetal 
bovine serum (FBS; Life Technologies, Carlsbad, CA), 100 U/ml penicillin, 100 µg/ml 
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streptomycin, and 2 mM L- glutamine all from Biological Industries. Cells were grown at 
37ºC in a 5% CO2 atmosphere. 
 
2.3. Cell Viability Assay 
 
 Cell viability was determined by MTT assay using 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Sigma-Aldrich Chemical Co., St. Louis, MO) (see 
Supplementary Material and Methods). 
 
4.4. Hoescht Staining 
 
 Cell morphology was evaluated by fluorescence microscopy following Hoescht 33342 
DNA staining (Sigma-Aldrich Chemical Co., St. Louis, MO). Cells (2x105 cells/ml) were 
treated or not with PG for 24 h. They were washed in PBS and resuspended in 2 µg/ml 
Hoescht 33342 and incubated for 30 min at 37 ºC in the dark. Then, cells were washed in PBS 
and examined under a Carl Zeiss Jena microscope. 
 
2.5. Kinase Profiling 
 
 Kinase profiling was performed by The National Centre for Protein Kinase Profiling 
(MRC Protein Phosphorylation Unit, Dundee, UK). All kinase assays were carried out using a 
radioactive (33P-ATP) filter-binding assay in duplicate. Screening was carried out at 10 µM 
and industry standard QC procedures were used to validate each assay. 
 
2.6. Immunoblot Analysis 
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 Cells were treated with prodiginines before insulin (Sigma-Aldrich Chemical Co., St. 
Louis, MO) stimulation. Adherent and floating cells were lysed in buffer (50 mM Tris pH 7.5, 
60 mM glycerophosphate, 20 mM sodium pyrophosphate, 2 mM EGTA, 5 mM EDTA, 30 
mM NaF, 1 mM orthovanadate, 1 mM DTT, 1% Triton X-100, 1 mM PMSF, 5 µM pepstatin 
A, 10 µM leupeptin). Protein concentration was determined with the BCA protein assay 
(Pierce, Rockford, IL) using bovine serum albumin as standard. 40 µg of protein extracts was 
separated by SDS-PAGE and transferred to Immobilon-P membranes (Millipore, Bedford, 
MA). Immunoblots were developed with primary antibodies according to the manufacturer’s 
instructions (see Supplementary Material and Methods). DMSO was used as a control. 
 
2.7. Immunoprecipitation and Non-radioactive Kinase Activity Assay 
 
 mTORC1 and mTORC2 complexes were immunoprecipitated from SK-MEL5 cells 
(see Supplementary Material and Methods). Immunoprecipitates were assayed against 
recombinant protein AKT1 and p70-S6K1 (Invitrogen, Carlsbad, CA), respectively, in a final 
volume of 30 µl containing 50 mM Tris pH 7.5, 10 mM magnesium chloride and 10 µM ATP 
which was incubated for 30 min at 30ºC with gentle shaking. Assays were stopped by addition 
of 5 µl Laemmli buffer and samples were then heated to 100ºC for 5 min. Samples were 
loaded on SDS-PAGE gel and analyzed by immunoblotting. 
 
2.8. Surface Plasmon Resonance (SPR) Assays 
 
 SPR assays were performed using Biacore T-100 (see Supplementary Material and 
Methods), which is a sensitive, high-performance, flow-cell-based SPR biosensor used for the 
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analysis of protein-protein or protein-small molecule interactions (22). This system 
incorporates software wizards which assist with the analysis of every interaction parameter, 
including kinetic and affinity evaluation and determination of binding specificity. 
 
2.9. Theoretical Methods 
 
 Using two separate computational approaches, 1) Blast + Modeller and 2) I-TASSER, 
we developed a homology modelling procedure for mTOR. Both approaches identified 
templates from the PI3K protein kinase family with 24-28% identity, and both built similar 
models. Additionally, two control in silico models from the PI3K family, PDK1 
(pdbcode:2PE1) and PKC-alpha (pdbcode:3IW4), were chosen for the protein-ligand 
simulations (see Supplementary Material and Methods). 
 After preparing the models, we performed a cavity search with SiteMap, which 
confirmed the ATP binding site as the top ranked binding cavity, followed by initial rigid 
ligand docking with Glide (23). For PDK1 and PKC-alpha we docked the crystallographic 
ligands together with PG. For mTOR we docked PG, OBX and PP242, a ligand that inhibits 
mTOR with an IC50 of 8 nM (24). The induced fit was modelled by 600 iterations with PELE 
(Protein Energy Landscape Exploration), a stochastic method of mapping large 
conformational rearrangements and induced fit events in protein-ligand interactions (25). To 
map the change in affinity after the protein-ligand induced fit, the PELE results were clustered 
and representative structures were redocked with Glide.  
 
2.11. Statistical analysis 
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 For analysis of activity kinasa, results are expressed as the mean ± S.D. of three 
independent experiments. Statistical analysis (ANOVA) was carried out with the Statgraphics 




3.1. Prodiginines induce cell death in melanoma cells 
 
 To determine whether prodiginines could be potential melanoma chemotherapeutical 
agents, we first examined their effect on two melanoma cell lines obtained from different 
stages of melanoma progression according to the broadly accepted Clark model (26). We 
examined SK-MEL-28 (radial growth phase) cells derived from an in situ melanoma. We then 
examined the next progression stage SK-MEL-5 (vertical growth phase) cells derived from a 
metastatic site (axilary node) of a melanoma-bearing patient. 
To compare the cytotoxic-inducing potential of PG and OBX on melanoma cells, we 
treated SK-MEL-28 and SK-MEL-5 cells with both compounds at concentrations ranging 
from 1 µM to 8 µM for 24 and 48 h. Cell viability was reduced by PG in a dose-dependent 
manner. PG showed a half inhibitory concentration (IC50) value of 4.51 ± 0.47 µM and 1.02 ± 
0.15 µM in SK-MEL-28 and SK-MEL-5 cells, respectively (Fig. 1A and 1B).  In contrast to 
PG, OBX had little effect on cell viability at 24 h. At 48 h of treatment, OBX showed an IC50 
value of 2.2 µM ± 0.43 and 1.8 µM ± 0.21 in SK-MEL-28 and SK-MEL-5 cells, respectively. 
Previous studies showed that OBX mediates cell death through the induction of 
autophagy and subsequent activation of apoptosis (27). Therefore, we analyzed which cell 
death mechanism was triggered by PG, using caspase-3,-9 and LC-3 proteins as apoptotic and 
autophagic markers, respectively. After PG treatment, the cytosolic form of LC-3 (LC-3 I) 
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disappeared and the form conjugated to phosphatidylethanolamine (LC-3 II) appeared, in a 
dose-dependent manner (Fig. 1C). It has been reported that LC-3 II is recruited to 
autophagosomal membranes, thus participating in autophagy (28). LC-3 II was induced at 
shorter time exposures than the activation of caspase-9, indicating that both processes are 
triggered, but that autophagy precedes apoptosis. Moreover, caspase-3 proteolysis and the 
formation of apoptotic bodies corroborate the apoptotic process (Fig. 1D). 
In addition, these results demonstrate that the cytotoxic effect mediated by PG is 
higher than by OBX in melanoma cells, especially in SK-MEL-5. 
 
3.2. Regulation of PI3K/AKT/mTOR and MAPK pathways is mediated by prodigiosin. 
 
 To analyze the potential of prodiginines as protein kinase regulators a kinase profiling 
procedure was performed. The results showed that PG (10 µM) suppressed the activity of few 
protein kinases from a panel of 65 protein kinases encoded by the human genome. The 
proteins that were significantly inhibited (> 70%) were AKT, ribosomal S6 kinase (RSK)-2, 
mitogen and stress activated protein kinase (MSK)-1, serum glucocorticoid-inducible kinase 
(SGK)-1, calmodulin-dependent kinase (CaMK)-1 and Bruton´s tyrosine kinase (Btk) (29, 
30). All these proteins participate in PI3K/AKT/mTOR and MAPK pathways. Interestingly, 
other proteins closely related to these pathways such as PDK1, insulin growth factor (IGF)-I 
receptor, MAPK protein kinases (extracellular related kinases (ERK)-1/2, p38, c-Jun N-
terminal kinase (JNK)-1/2) and inhibitor of nuclear factor kappa-B kinase (IKK) were not 
inhibited. Unfortunately, other proteins of interest such as mTOR were not included in this 
kinase profiling (Fig. 2A). These results characterize PG as a multi-kinase inhibitor, and they 
provide a range of new potential targets of prodiginines, all of which play a critical role in the 
control of the cell cycle and tumor progression. 
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 To elucidate the specific molecular mechanisms that induce the cytotoxic effect of 
prodiginines, and based on the kinase profiling results, we studied the effect of PG and OBX 
on PI3K/AKT/mTOR and MAPK pathways in melanoma cells. Both pathways regulate 
melanoma cell death and proliferation (26). 
 We first examined the activation of the two key effector kinases of these pathways, 
AKT and ERK1/2. Phosphorylation levels of these kinases were higher in SK-MEL-28 than in 
SK-MEL-5 cells (Fig. 2B). These differences in the up-regulation of pro-survival protein 
kinases might explain why resistance to prodiginine treatment depends on the cell line. 
 We then analyzed the effect of PG on both pathways. Cells were treated with PG at the 
IC50 concentrations established as described above. PG reduced AKT phosphorylation on 
S473 in a time-dependent manner. Nevertheless, only a slight effect was observed on T308, 
and PG had no effect on PDK-1 or ERK1/2 (Fig. 2C). These results, together with the kinase 
profiling, indicate that mTOR signaling might be down-regulated in the presence of 
prodiginines. 
 
3.3. Inhibition of mTOR signaling by prodiginines in melanoma cells 
 
 After observing significant inhibitory effects of PG on AKT, we sought to confirm the 
inhibition of the AKT/mTOR/p70S6K signaling pathway by prodiginines in melanoma cells. 
Thus, we examined the effect of prodiginines on the main regulators and substrates of this 
pathway. As shown in Figure 3A, both PG and OBX inhibited mTORC2 activity, leading to 
an inhibition of the insulin-stimulated phosphorylation of AKT and PRAS40. Nevertheless, it 
was necessary to use higher doses of OBX (10 µM) to obtain same effects as PG at 1 h of 
treatment. Insulin-stimulated phosphorylation of PRAS40 at T246 by AKT suppresses its 
mTORC1 inhibitory activity. Therefore, insulin stimulation activates mTORC1 and increases 
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p70S6K phosphorylation (16). After treatment with prodiginines, p70S6K and 4E-BP1, which 
are directly regulated by mTORC1 were also dephosphorylated. Dephosphorylation of mTOR 
effectors suggests that prodiginines inhibit mTOR pathway.  
 To further confirm that prodiginines target mTOR pathway, we first determined 
whether knockdown of mTOR (sh-mTOR) or raptor (sh-raptor) in SW-480 cells prevented the 
cytotoxic effect induced by prodiginines. Knockdown of mTOR or raptor resulted in 47% or 
74% reduction in endogenous protein expression, respectively, compared with stable control 
cells (sh-φ) (Supplementary Fig. 2 A and B). The functional depletion of mTOR pathway was 
confirmed by decreased phosphorylation levels of p70S6K and AKT in mTOR and raptor 
knockdown cells (Supplementary Fig. 2C). According to protein depletion levels in both cell 
lines, results showed higher p70S6K inhibition in raptor knockdown cells. Complete AKT 
inhibition was observed after treatment with PG or OBX at 4 µM for 1 h. After 6 h of 
treatment with both prodiginines, protein expression down-regulation was induced in both 
mTOR effectors. 
We next assessed whether depletion of mTOR activity prevented from prodiginines-mediated 
cell death. Stable control cells and knockdown cells were treated with a range of 
concentrations (0-4 µM) of PG or OBX for 24 or 48 h (Supplementary Fig. 3A and 3B). 
Results showed greater cytotoxic effects in sh-φ cells after treatment with PG than OBX, as 
observed in melanoma cells. Nevertheless, the most significant results were obtained after 48 
h of treatment. At 4 µM of PG or OBX, sh-mTOR and sh-raptor cell death was reduced in a 
∼35-40% compared with sh-φ cells (Fig. 3B), demonstrating that mTOR complexes are 
critical for prodiginines cytotoxic effect.   
 
3.4. Prodiginines counteract the activation of the S6K-1/IRS-1 negative feedback loop 
through mTORC1 and mTORC2 inhibition. 
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 We further examined the ability of PG and OBX to inhibit mTORC1 and mTORC2 
complexes in melanoma cells. Inhibition of mTORC1 induces activation of S6K-1/IRS-1 
negative feedback (19). Dual inhibition of mTORC1 and mTORC2 might counteract this 
mechanism. With this in mind, we first compared the effect of both compounds with that of 
rapamycin, which inhibits mTORC1, leading to an increase in AKT phosphorylation through 
an IGF-1R-dependent mechanism. As expected, rapamycin alone decreased phosho-p70S6K 
levels, while increasing phospho-AKT levels. The greatest effect of rapamycin was seen at 
100 nM (Supplementary Figure 4). As a further comparison, we co-treated both cell lines with 
PG (IC50) or OBX (10 µM) and 100 nM rapamycin for 1 h, before insulin stimulation. In 
contrast to both prodiginines alone, treatment with rapamycin induced a stronger decrease in 
the phospho-p70S6K levels, suggesting that mTORC1 is not completely inhibited by PG or 
OBX (Fig. 4A). Nevertheless, in both cell lines, PG rather than OBX counteracted the 
activation of this feedback loop, leaving AKT quite dephosphorylated. 
To evaluate the inhibition on mTORC2 and mTORC1 complexes, further kinase activity 
assays were performed. We isolated active mTORC2 and mTORC1 complexes from 
melanoma cells after insulin stimulation. Active mTORC2 and mTORC1 were 
immunoprecipitated from the lysates using anti-rictor and anti-raptor antibodies, respectively. 
mTORC2 activity was analyzed using recombinant AKT as substrate. The inhibition of 
mTORC2 by PG or OBX resulted in a loss of AKT phosphorylation (Fig. 4B). We next 
measured the effect of both molecules on mTORC1 activity using p70S6 as a substrate (Fig. 
4C). Both prodiginines markedly inhibited both mTOR complexes. The strongest inhibition 
(89%) was induced by PG on mTORC2 (Fig. 4D).  
 
3.5. Kinetic characterization 
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 In order to further characterize the prodiginines as mTOR inhibitors, we first 
monitored the interaction between mTOR and prodiginines by real-time interaction analysis. 
We used Surface Plasmon Resonance (SPR) assays, which allow kinetic and affinity 
evaluation and determination of binding specificity between proteins and small molecules 
(22). 
 For binding experiments, we first immobilized the recombinant protein mTOR (aa 
1360-2549) on a sensor surface. The analytes (PG and OBX) were then injected in solution 
over the surface. Changes in SPR response were detected even at nanomolar concentrations. 
The interactions of small molecule inhibitors with mTOR were analyzed, providing kinetic 
and affinity data in the nanomolar range (Fig. 5A and 5B). The same order of magnitude in 
the affinity data (KD) and the low dissociation rates (Kd) suggest that both molecules form 
similar specific and stable binders. 
Small molecule specificity was tested by performing interaction analysis between 
these compounds and another protein kinase: AKT. In this case, the data did not fit this 
interaction model using PG as analyte. Moreover, using OBX no high-affinity saturable 
component was obtained (Supplementary Fig. 5). These marked differences in the 
characteristics of the interactions compared to mTOR suggest that stable binding does not 
occur between prodiginines and AKT. 
 
3.6. In silico docking prediction 
 
 To further characterize the interaction of prodiginines with mTOR, we developed a 
homology model of the active site sequence (residues 2131-2516). PDK1 and PKC-alpha 
were used as control systems. Fig. 6A shows the Glide docking scores before and after the 
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PELE run modeling the induced fit procedure, together with the active site RMSD along the 
fit process, for all systems and ligands. As expected, we obtain good initial docking scores for 
the two crystallographic ligands in PDK1 and PKC-alpha, -9.2 and -12.0, respectively. 
Furthermore, when comparing the docked structure for each ligand with its crystal structure 
we obtained an RMSD of ~0.3Å. Such agreement, however, is expected when a ligand is 
docked into its crystal structure. The induced fit procedure does not significantly change the 
scores, and only introduces slight changes to the protein-ligand structures in the active site: 
1.1Å and 1.3Å for LAA and LW4, respectively. Thus, the control test with both 
crystallographic ligands indicates good affinities and small induced fit reorganization. Next, 
we applied the same protocol to PG and found significantly lower initial binding scores: -6 to 
-7. The initial models, however, were taken from the crystal structures with bound ligands. 
Thus, they are biased towards the crystal ligands, requiring some induced fit in order to adapt 
to PG. For this purpose PELE was used (25). The induced fit procedure increased the RMSD 
but did not substantially improve the affinity for PG; the control experiments support the 
absence of inhibition in PDK1 and PKC observed in the kinase profiling. 
Regarding the mTOR ligand docking, the initial docking score of pp242, PG and OBX is 
about -7 to -8, similar to the value measured for PG in our in silico control assays. For mTOR, 
however, the induced fit procedure (the same used for PDK1 and PKC-alpha) introduced 
significant changes. We observe a clear increase in binding affinity along with a significant 
active site adjustment, the RMSD increases to 2.1 and 2.3 for PG and OBX, respectively. For 
all three ligands we obtained scores which are similar to those obtained for the crystal ligands 
in PDK1 and PKC-alpha. Thus, our simulation studies corroborate recent observations on 
pp242 (24) and also support our experimental findings with PG and OBX. 
In Fig. 6B and 6C we display the detailed atomic view of the induced fit of the PG- and OBX-
mTOR complex, where we can observe several recognition motifs. For example, in the fit PG-
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mTOR complex, the hydrophobic environment around the pentyl side chain includes Ile2500, 
Ile2559 and Val2504. We also observe a stacking interaction between His2340 and the PG 
pyrrole rings. The most interesting feature, however, is the “H-bond ring” created by the 
alcohol side chain in Ser2342 and the two extreme pyrrole nitrogens. In silico mutation of this 





 Prodigiosin (PG) and obatoclax (OBX), both belong to the prodiginine family, which 
are pyrrole alkaloids of bacterial origin. Both molecules are promising candidates as 
anticancer drugs, since they have pro-apoptotic activity in a broad range of human cancer cell 
lines (1). Although they are currently in pre-clinical and clinical trials, respectively, further 
studies are necessary to identify the molecular target involved in their anticancer activity. It 
was hypothesized that OBX has more complex effects on melanoma cells than merely binding 
to and inhibiting antiapoptotic Bcl-2 family proteins (3). In the present report, we considered 
other survival signals to further understand the mechanism of action of prodiginines. We 
studied the prodiginine-mediated cytotoxic effect in different stages of melanoma progression. 
PI3K/mTOR and MAPK signaling pathways are involved in growth and progression in 
melanoma. Deregulation of these pathways is associated with resistance to apoptosis, 
increased cell growth, cell proliferation and cell energy metabolism. It also confers to 
melanoma resistance to many chemotherapeutic agents (26). Prodiginines overcome this 
resistance, and are thus cytotoxic in both cell lines. Moreover, deregulation of these pathways 
might explain the higher IC50 value of SK-MEL-28 cells compared to SK-MEL-5 cells. 
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Melanoma cells were more sensitive to PG than to OBX. Our results are consistent with 
previous reports where melanoma cells rendered more sensitive to OBX-induced apoptosis 
only in combination with molecules that induce reticulum stress, but not as a single agent 
(31). It was also described that OBX induces autophagy before apoptosis (27). Our results 
show that PG also activates both mechanisms. Moreover, cytotoxic effect of prodiginines was 
partially prevented by mTOR and raptor proteins depletion, concluding that prodiginines-
induced mTOR pathway inhibition leads to cell death. We have characterized the effect of 
both prodiginines on critical elements of mTOR signaling such as AKT, PRAS40, p70 S6K 
and 4E-BP1, as well as on different compensatory mechanisms which link PI3K/mTOR and 
MAPK signaling (18, 20). Our results demonstrate that prodiginines target mTOR pathway. In 
contrast to rapamycin, prodiginines counteract the feedback loop triggered by mTORC1 
inhibition, which leads to AKT activation through IGF-1/IRS-1 signaling (19). The 
effectiveness of prodiginines relies on their ability to inhibit mTOR activity. Therefore, the 
suppression of mTORC1 as well as mTORC2 activity implies a reduction of phosphorylation 
of AKT at S473. 
 The kinetics and affinity evaluation revealed high-affinity binding between mTOR and 
prodiginines. Nevertheless, although mTOR is a validated target for the treatment of cancer, it 
might be necessary to develop more effective prodiginine-derivates with improved chemical 
properties that increase their bioavailability. 
 The second generation of mTOR inhibitors targets the ATP site. These compounds 
suppress AKT phosphorylation, leading to a stronger antiproliferative effect than that of 
rapamycin (18, 32). Therefore, prodiginines effect might be closer to the second generation of 
mTOR inhibitors. Thus, it will be interesting to compare prodiginines with other small 
molecules such as AZD-8055 (AstraZeneca), INK-128 (Intellikine), OSI-027 (OSI 
pharmaceuticals) or pp242 which also block both mTORC1 and mTORC2 complexes. pp242 
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is structurally similar to prodiginines (24).  In silico models suggest that prodiginines, like 
pp242, could interact in the active-site of mTOR and provided several of the recognition 
motifs involved in their interaction. Moreover, these models also illustrate the importance of 
the alcohol side chain and the two extreme pyrrole nitrogens of the prodiginines for the 
interaction on Ser2342 of mTOR. 
 These findings described here by PG and OBX as mTORC1 and mTORC2 inhibitors 
contribute to our understanding of the molecular mechanisms of action of both molecules and 
provide data about their structural properties that will allow the development of more-
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Fig. 1. Cell death in PG- or OBX-treated SK-MEL-28 and SK-MEL-5 cells. (A) 
Cytotoxic effect of PG is higher than that of OBX. Cells were treated with a range of PG or 
OBX concentrations (0-8 µM) for 24 and (B) 48 h. Cell viability was determined by MTT 
assay. The percentage of viable cells was calculated as the ratio of A570 between treated and 
control cells. Values are shown as mean ± S.E.M. of three independent experiments 
performed in triplicate. (C) PG induces activation of both autophagic and apoptotic 
mechanisms. Cells were treated with PG IC50 and cell extracts were assayed for LC-3, 
caspase-9 and procaspase-3 expression by Immunoblotting. Actin was used as loading 
control. (D) PG induces apoptotic body formation and nuclear condensation. This was 
observed through Hoescht staining in cells treated with PG IC50 for 24 h. 
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Fig. 2. Effect of PG on PI3K/AKT/mTOR and MAPK survival pathways.  (A) PG 
induces inhibition of some PI3K and MAPK-related protein kinases in vitro. Kinase 
assays were performed by the MRC Protein Phosphorylation Unit. PG 10 µM was screened in 
duplicate against a panel of 65 protein kinases. All assays were carried out using a radioactive 
(33P-ATP) filter-binding assay. (B) PI3K/AKT and MAPK pathways are activated in SK-
MEL28 more strongly than in SK-MEL-5 melanoma cells. Phosphorylation and total 
protein levels of AKT and ERK1/2 were visualized by Immunoblotting. Actin was used as a 
loading control. (C) PG-induced AKT but not ERK1/2 dephosphorylation. SK-MEL-28 
and SK-MEL-5 cells were treated with PG at a concentration of IC50 for 15 min to 1 h. 






Fig. 3. Prodiginines target mTOR pathway. (A) Effect of prodiginines on critical 
effectors of PI3K/AKT/mTOR pathway in melanoma cells. SK-MEL-28 and SK-MEL-5 
cells were deprived for 24 h and treated with PG or OBX at the indicated concentrations for 1 
h before insulin-stimulation at 1 µM for 30 min. Cell extracts were analyzed by 
Immunoblotting. Actin was used as loading control. (B) Inhibition of mTOR activity 
prevents from prodiginines-mediated cell death.  Stable control and knockdown cells were 
treated with PG or OBX at 4 µM for 48 h. The percentage of viable cells was calculated as the 
ratio of A570 between treated and control cells. Values are shown as mean ± S.E.M. of three 











Fig. 4. Prodiginines counteract S6K1/IGF-1R negative feedback loop through mTORC1 
and mTORC2 inhibition. (A) Effect of PG on S6K1/IGF-1R negative feedback loop in 
melanoma cells. Before insulin stimulation, deprived cells were pre-incubated with 
rapamycin 100 nM for 15 min and prodiginines were then added at the indicated 
concentrations for 1 h. (B) Prodiginines inhibit mTORC2 and mTORC1 complexes. 
Active mTORC2 and mTORC1 complexes were immunoprecipitated from insulin-stimulated 
SK-MEL-5 cells using anti-rictor or (C) anti-raptor antibodies, respectively. 
Immunoprecipitated were incubated with recombinant AKT or p70S6K (20 ng), 50 mM Tris 
pH 7.5, 10 mM magnesium chloride, 10 µM ATP and PG or OBX, both at 10 µM for 30 min. 
Kinase reaction was stopped with Laemmli buffer (5X) and phosphorylation levels of p70 
S6K or AKT were visualized by Immunoblotting. (D) Data is expressed as the percentage of 
phospho-AKT or phospho-p70S6K levels (normalized by AKT or p70S6K levels), 





Fig. 5. Kinetic characterization of PG and OBX binding to mTOR by Surface Plasmon 
Resonance (SPR) assays. (A) PG or (B) OBX were injected at a range of concentrations 
between 0.06 µM to 1 µM over immobilized mTOR (aa 1360-2549). Sensograms and curve 
fit (black lines) are shown. Kinetics and affinity evaluation of these sensograms showed 
affinity (KD=Kd/Ka) constants of 416 ± 49 nM for PG and 355 ± 121 nM for OBX, 
respectively. RU, resonance units.  
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Fig. 6. In silico model. (A) Initial and after PELE (induced fit) scores obtained with Glide for 
the different systems and ligands. Also show is the RMSD along the induced fit process. 
RMSD was computed as all heavy atom within 10Å of the initial docking position (units in 
angstroms). (B) Detailed view of the PG-mTOR and (C) OBX-mTOR induced fit complex. 
 
